Respiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections like pneumonia and bronchiolitis in infants and young children. Traditionally there have been no approved treatments for RSV infections, with care being largely supportive. But the landscape is quickly changing.
The FDA recently approved Beyfortus (nirsevimab), the first immunoprophylactic to prevent RSV disease in newborns, infants and toddlers. On the RSV vaccine front, FDA also approved GSK‘s (NYSE:GSK) Arexvy. Other RSV vaccine candidates are waiting in the wings.
A shift in the RSV treatment landscapeBeyfortus is a monoclonal antibody developed by AstraZeneca and Sanofi that provides protection against RSV with a single intramuscular injection. It is the first innovation in RSV prevention in over two decades. Until recently, the only preventive therapy on the market was Synagis, a monoclonal antibody used to help prevent serious lung disease from RSV in …